COMPANY RESEARCHThe website describes EPI-326 as a tissue-selective EGFR bispecific antibody degrader in an ongoing Phase 1 NSCLC/HNSCC trial, NCT07462377.
The formal 2026-01-08 announcement disclosed an initial $107 million Series B; a later company LinkedIn update states $122 million. The extension closing date and incremental amount were not identified; the two figures are not added.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
The website describes EPI-326 as a tissue-selective EGFR bispecific antibody degrader in an ongoing Phase 1 NSCLC/HNSCC trial, NCT07462377.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| EPI-326 / EpiTAC | EGFR · NSCLC / HNSCC | Phase 1 | IND / clinical entry disclosed; public human results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
